Fate Therapeutics (FATE) Tops Q4 EPS by 1c

Fate Therapeutics (NASDAQ: FATE) reported Q4 EPS of ($0.30), $0.01 better than the analyst estimate of ($0.31).

For earnings history and earnings-related data on Fate Therapeutics (FATE) click here.

You May Also Be Interested In

• Key things to know ahead of SK Hynix’s blockbuster US listing
• Mizuho upgrades five below on valuation, sees over 20% upside
• Trinity Capital posts $709M in new commitments for Q2 2026